YouTube Transcript:
RUMA Agriculture Webinar - The future for vaccine Availability for the UK animal health market

Skip watching entire videos - get the full transcript, search for keywords, and copy with one click.

Video Transcript

Video Summary

Summary

Core Theme

This webinar addresses the critical issue of vaccine availability in the UK animal health market, highlighting the challenges faced by stakeholders and outlining a collaborative, multi-year strategy to improve supply, uptake, and innovation.

Mind Map

Click to expand

Click to explore the full interactive mind map • Zoom, pan, and navigate

everyone. We've got a number of people

joining. So I'm just going to give it a

few minutes to let everybody in from the

lobby. But welcome to uh this the second

webinar in our four webinar series on

every Wednesday of November.

Um my name is Chris Lloyd and I'm

Unfortunately, they they gave me control

of some of the buttons today. So, um

you'll just have to forgive me. We

should be letting everybody in without

So good morning everyone. As I said, my

name is Chris Lloyd and I'm Secretary

General for Room Agriculture and I'll be

chairing today's session. Um before we

move on, there were just a few bits of

housekeeping to share. The webinar is

being recorded and will be published on

the Rumor Agriculture website as soon as

we can after the session.

Um, we should have everybody's uh

microphones and cameras turned off if

I've got the settings correct, but just

in case, please check that you uh your

microphones off and your cameras off as

well. We have a lot to share today and

due to the limited availability of some

of our speakers, um we actually have

some pre-recorded elements to today's webinar.

webinar.

Um this means that uh our live speakers

today are limited or access to them. Uh

but we will we do have the Q&A function

turned on and if you have any questions

for any of the speakers or the the

presenters from the VMD in the recorded

sessions, please do leave your questions

in the Q&A and we will pass them on to

the speakers for them to um consider

them after today's session.

But just to manage your expectations,

it's unlikely that we'll be able to

answer those questions today.

So our webinar is entitled the future

for vaccine availability for the UK

animal health market. And as I've said,

this is the second in a series of four

live webinars that rumor agriculture is

delivering this month. Our first webinar

last week was a panel session and we

considered some of the current

opportunities and challenges influencing

the responsible use of medicines and we

have two more to come. Next week we have

the rumor um rumor agriculture targets

task force 2 final reports. So that's

the end of our five-year um phase two

for TTF. uh and the VAS report from the

VMD which uh gives us information on the

veterary antibiotic um retail sales and

surveillance. That's on Wednesday the

19th at 11:00 a.m. And uh the final

webinar on Wednesday the 26th of

November will be the third phase of

targets TTF3 the new targets that the

sectors are setting for the next 5

years. We hope you can join us for those

but if not they will be recorded and you

can watch them on our website.

back to today and our focus on is on

vaccine availability for the UK animal

health market which is a topic that

rumor alliance members have been have

been increasingly raising with us over

the last few years.

I'm going to hand over shortly to uh the

rumor agriculture communications manager

Mary Bourne who's going to share with us

the results of a survey we carried out

earlier this year to understand more

about the vaccine supply situation in

the field at grassroot level.

We're then really lucky to have a

manufacturer's perspective from MSD

delivered by Rebecca Fuz Fuzzleman who's

the plant manager for the MSD UK

facility at Milton Kees.

We then have two pre-recorded sessions.

Uh a presentation from Cla Stratford

who's the principal veterary advisor um

and she's also head of the research

innovation sustainability and evidence

team at the VMD. And she's going to be

giving us details of the uh VMD's

proposed 5-year strategy. That's

followed by a Q&A session which I did

with Claire and Suzanne Eckford um both

of the VMD when where we discuss a range

of questions about both the vaccine

strategy and its journey ahead.

So to our first presentation I'd like to

introduce Mary Bourne who is the rumor

agree manager and she's going to be

sharing the results of the vaccine

survey we carried out earlier this year.

Mary I'll hand over to you.

>> Thanks Chris. Um good morning everyone.

Um, great to see so many people here

today. I'll just load up um the screen.

Um, Chris, if you can just confirm when

uh that is on screen, please.

>> Yeah, we can see that fine. Thanks, Mary.

Mary.

>> That's brilliant. Thank you. Um, so as

Chris said um earlier this year, uh,

Rumor Agriculture

um, carried out um, a survey um, and I

guess just to manage expectations, it

was a very top level survey. It wasn't

um designed to be in any way kind of

scientific. Um but we wanted to do this

to try and build um a deeper

understanding um of what's happening on

the front line. Um as Chris said, at

grassroots um with the availability um

challenges um surrounding vaccines. Um

as we all know um vaccines play um a key

role in safeguarding the health and

well-being of animals um and therefore

limited or no supply um which is

something that has been reported more

frequently over the past few years by

numerous livestock sectors um can um

have widespread implications on animal

well-being. And that could include uh

for example an increase in antibiotic

use to manage conditions um that may

otherwise have been prevented with vaccinations.

vaccinations.

Um so that kind of brought us to the

point where we we as REMA agriculture

were hearing um from from our members um

and other stakeholders about um some of

these um shortages. Um and we wanted to

try and do something and build a like I

said a deeper understanding. Um so back

in May, early May this year, we um uh

developed a set of questions um and

launched those um and our our target

audience um was to gather information

um from vets, farmers and um SQPs um

otherwise referred to as animal medicine

advisers because we know um they they

are certainly on on the front line of of

prescribing advice um around um

vaccinations. Um so hopefully that just

gives you an initial kind of picture and

and background as to what what was

driving us um to do the survey. So

moving on now um to um start to share

some of the the results. Um uh we had a

great response um across the the various

stakeholder groups and you can see on

screen um a breakdown um we had um 191

um uh respondents overall um and we

hadn't got any benchmarks. So really

anything over 100 we were really pleased

with. Um and as you can see there we had

a spread of um SQPs uh farmers and vets.

Um and we had some that selected other

um and when we dug a little deeper those

were roles generally in kind of more of

a management um or gen general role um

within the industry. Um so a good a good

spread um from the stakeholders that we

absolutely wanted to hear from.

So moving on then to um some of the um

responses we got to the various

questions. Um first of all um we were

asking about um the the awareness of of

any shortages of vac vaccines and

delivery disruption um and whether that

has affected um your ability to use or

prescribe vaccines for the prevention of

animal disease um across the following

time frame. So we we we'd heard um

various um bits of feedback about uh the

problem might be getting worse. Um so

this was the rationale for trying to get

a bit of a feel for you know is is has

it been getting worse over a certain

time frame and we went back to um around

2022 um as an initial um overview. And

you can see there um that that generally

um there's been a there's been a a

worsening problem um in in recent years

um progressively um since since 2022

um and I guess just to kind of further

validate that um we we we asked a very

clear question um is is is vaccine

availability worse now um than five

years ago and and and an overwhelming

94% of respons respondents stated that

Um, a big part of of of this survey was

also trying to understand not only about

the impacts but also what which vaccines

in particular um were um being affected

or or were in short supply or disrupted

supply. Um, and I just give a quick

shout out now on the next slide um, to

our colleagues at the VMD who helped us

analyze some of the data um, and have

helped us um, define kind of the top 10

um, that the survey um, picked up um,

from the responses. Um, and you can see

there um, what what that top 10 list

looks like. Um we also looked um um

across the different stakeholder groups

um and whether there was a difference in

what they were saying but broadly there

wasn't. Um so across farmers, vets and

SQPs there was quite a lot of

consistency in in this um feedback

across the types of vaccines that were

in short supply. Um and as you can see

most of the reported disrupted vaccines

are those utilized in the sheep sector.

um nine of the top 10 most reported

disrupted vaccines are categorized as

category 1 vaccines under Noah guidance.

Um so again that just gives us um a bit

more insight that that that we hadn't

got when we were hearing the feedback

initially from the sectors and I think

this um we know that this is going to be

prove very useful um as as work

continues on on developing support in

Um so we also then uh wanted to explore

a little bit more about um the impact.

Um so the next question um relates to

whether uh the vaccine availability

issues have been a limiting factor in in

an in the ability to prevent disease um

in in animals under the respondents care

over the past um two to three years. Um

and again quite a strong um response

there of 79% that stated that that had

Um and then the next the next question

again is just trying to go into a little

bit more detail and and you'll see that

we had some some more free text answers

um in in this particular case. Um so

this is looking at the negative impacts

on an animal health as a result of of

vaccine availability issues. Um and 66%

of respondents um said that they they

have either experienced or are aware of

negative impacts on animal health as a

result of of those vaccine availability

issues. Um and the subsequent question

to that was we asked uh respondents to

elaborate a little bit more if they felt

they were able to. Um and you can see a

summary there of of just some um just

some of those key um pieces of feedback

that we got. Um, for example, more

deaths in flocks and herds, increased

abortion, increase in lameness,

sudden and unexplained death in

unvaccinated herds, um increase in use

of antibiotics um uh due to increase in

in for example disease like diseases

like um pneumonia also that lack of

immunity being passed on um in the

absence of of vaccines being available

and used. Um and then another point that

that that started to come out was um uh

disinterest and apathy potentially um on

on on vaccination um following supply

issues um playing out potentially in a

way that that might be giving um a false

sense of security. Uh so if if vaccines

haven't been available and there hasn't

been any immediate issues um then um the

concern is will when when availability

is better will will farmers then want to

use them um again or will they not re

not not feel that there's a necessity to

do so when of course we we know that is

important. Um so that's another emerging

theme I think is really important um

Um keeping with the impacts um uh

obviously if there are going to be

impacts in terms of um some of that

finer detail we were hearing on the

previous slide um then obviously that

that can also uh result in financial

impacts at farm level um as well. Um and

again we asked this as a free text

question broadly. Um and um you can see

there loss of livestock um as a

financial impact um by having to buy

larger pack sizes um uh fewer lambs to

sell. But I think one of the really

telling ones on this slide is is a quote

that came in um which said you do not

get paid for dead animals. You have to

pay that pay to get them taken away. um

um very emotional um uh statement as

well as factual in some cases there and

um uh whilst this is a snapshot um and

like I said it's very top level um

survey um I think that is quite a

poignant um um statement to have

received as part of this um survey feedback

feedback

um some other impacts as well disease

outbreak and obviously uh productivity

losses off the back of that um the cost

of having to implement um new vaccine

programs as well and or restart vaccine

programs all of which um uh have have

those financial impacts um um that was

was the basis of this question and like

I said this is just to give a bit of a

snapshot today um of the feedback um

So, moving on then um to the question

around um the current situation with

vaccine vaccine availability and whether

that's had a negative long-term impact

on UK animal health and welfare. And you

you can see there that um around that

72% of respondents said they felt it had

um just a small amount um said no. Um

and then some people sort of in the

middle around 26% were were not sure. Um

and and of course this is this is a

journey in terms of that that

availability issue that's been emerging

um over recent years. But again some

important insight that we got um we got

from the survey there.

Um but then um sticking with kind of the

similar the theme we started to explore

a little bit more um whether the lack of

availability in the respondents opinion

um uh may have caused an uplift in the

use of antibiotic antibiotics.

Um and you can see there on on the top

of the slide

um that that a high proportion um just

under half 47% did say um they felt it

had um we also had some that were were

unsure or hard to say there um uh and

may not be aware of any impacts at this

moment in time. Um but then when we

asked the respondents to I guess look

look forward um and whether an ongoing

shortage of vaccines um would result in

an increased use of antibiotics. You can

see that actually um the the result

there is is is much much higher in terms

of people saying yes. Um so I think

that's um again reinforces um the

concern that exists um around um the

disruption in in supply.

Um now moving on to um uh a UK vaccine

strategy. Now when we first launched the

survey back in May um this wasn't

something that um um was was formally

announced but um of course it is now. Um

so when we asked um the question um

there was certainly a resounding um

resounding support for the need um for a

vaccine strategy of 96% as you can see

on on screen there. Um but since then um

a lot of work has been being done by the

BMD um various workshops um with lots of

stakeholders from industry which has

been um brilliant um and the VMD has

have recently issued a statement of

intent um which is um a UK government

framework um and it was published in

September 2025

um to address um the challenges in the

availability of veterary vaccines

um and that sets out a strate strategic

approach for um cross- sector collaboration

collaboration

um to tackle uh the mismatches in supply

and demand um encourage innovation and

um try to move from a just in time um to

a more resilient just in case um supply

model um and this um will be followed by

a five-year action plan um to improve um

supply uptake um and innovation um in

veterary vaccines and uh Rumor

Agriculture has been pleased to be

working alongside inside the VMD um as

as one of many stakeholders um on this

important piece of work.

Um so just um coming back to um the the

the questions that we were asking back

in May um do you feel more investment is

needed in vaccines manufacturing? Um uh

again um quite a resounding um yes on

that and um we will be hearing more uh

more broadly shortly from the VMD and a

manufacturer um to talk a little bit

So, we also wanted to explore with our respondents

respondents

um um possible solutions um and um we

didn't want to put them on the spot, but

we we know um on the front line um uh

farmers, SQPs, and vets are are um are

dealing with um and trying to manage

through um supply um issues as and when

they do occur. So, we felt it was useful

to ask ask the respondents for some of

their views on on other possible

solutions. Um, and I certainly won't go

through all of them, and this isn't all

of them on screen that you can see, um,

today. Um but just to pick out some of

the key themes um uh reduction in red

tape and and trying to bring vaccines

into into the country forward planning

by manufacturers um and UKbased

manufacturing all very much um recurring

themes um in in the feedback that we

received um facilitate use of autogenous

vaccines. Um also looking at kind of

quantities and different um volumes of

quantities available. Um better planning,

planning,

efficiency of of processes and

manufacturing uh processes.

Um also um um a very consistent theme

was communication um and better

communication between um all

stakeholders really um across kind of

the v vaccine manufacturers, farmers and

vets as to when supplies might be in in

um short supply or when demand on the

front line might be coming up. Um and

that all important planning as well. Um

also alternative vaccines and making

those maybe more easily um available. um

trading relationships um and and

capacity for for manufacturing in the UK

was also um some consistent themes that

And then um entering the final few

questions now. Um we uh as I said

earlier this was about impacts and

there's lots of impacts we as we've just

covered whether that that's kind of

financial animal health and welfare um

but also we know that this can be quite

an emotive and worrying um uh uh

situation as well um because everyone

wants to achieve the best health and

welfare outcomes um for animals. Um so

asking the question around um whether

it's causing um concern, worry and

stress to to the stakeholders that

responded. You can see there that you

know again um a high proportion 85% said

said that it that it was um it was was

concerning um and and worrying um and

causing stress as well. Um

and then um finally um might seem like a

very obvious question to ask but again

we we had a very um responsive and

captive audience um how important are

vaccines in protecting the health and

well-being of our animals. Of course, we

all know that answer, but it's really

good to hear um that 95% um absolutely

uh feel it, feel um they are extremely

important in in protecting health and

well-being of of animals. Um so there's

a commitment there and I think an

absolute understanding that these are

important preventive medicines. Um and

um there's a need hopefully to ensure

that that reliable supply into the future.

future.

So that's everything on the survey and I

shall now hand back to Chris. Thank you Chris.

Chris.

>> Thanks Mary.

>> And ju just to sort of be clear as Mary

said at the beginning this wasn't um uh

an indepth analysis a um highly uh

technical sort of questionnaire. This

was about um this was about listening to

the Roman Alliance members who who were

expressing concerns about availability

and it was about trying to gather some

um uh information to underpin or to

explain or to give some insight into

those those concerns. Uh and I think one

of the important things is it it it

demonstrated that those concerns were

real but also that it's a really complex

issue. And one of the complexities

within that issue with the manufacturing

processes and that's why I'm really

pleased uh to be joined this morning by

Rebecca Fzenman uh from MSD uh who as I

explained she's the manufacturing plant

manager based here in the UK for MSD and

is well placed to explain some of those

complications from the manufacturers's

point of view in terms of the complex uh

production systems for vaccines. So

Rebecca, I'll hand over to you and I

think you're going to share your screen.

So I'll just give you a nod when that

comes up.

Brilliant. We can see that. >> Great.

>> Great.

>> Thanks, Rebecca.

>> Yeah, absolutely. So good morning. Um

really pleased to be here. Um and take

all that feedback obviously very

seriously. I think the one thing we can

all agree on is that we all want

vaccines for animals. um at the right

time when you need them at the right

cost point. So we're united in in that

journey to to make that happen. Um so

just a brief introduction about myself.

Um Rebecca Fussleman. I've been with MSD

for about 17 years. Um always in animal

health manufacturing. Um worked as a

technician. um and then a manager uh led

a functional work stream, a small site

and now am responsible for MSA MSD UK um

animal health manufacturing. So really

responsible for three sites here in the

UK um Milton Kees, Newberry and

Graveley. We are the biggest um animal

health vaccine manufacturer in the UK.

Um and uh we also do produce the two

vaccines that have caused uh the most uh

noise. So, uh, I really take this

opportunity today to to share with you,

um, what we're doing, what the

manufacturing process looks like, what

lead times look like, and essentially

how we can work together to optimize um,

that manufacturing work stream. So, just

a bit of brief background

I can. There we go. Um so just wanted to

show you um the site really here in

Milton Kees. Um so it's been an MSD site

since 2011. Um but you'll probably

potentially remember it as a sharing

plow or an intervet sharing plow or a

host um vaccine manufacturer but um

through series of acquisitions similar

vaccines um but now trading as MSD. And

Apologize I am having some technical

difficulties. There we go. Um so what do

we do here in the UK? Um we're a large

molecule line of business. Uh we focus

on aseptic and sterile technologies. Um

so here at the site we have six ferment

lines. Um and that's used for both

aerobic and anorobic bacteria. Um we

produce about 24 antigens um for

integrated process teams products

meaning that's the that's the team that

creates all the manufacturing for

bacterialbased antigens for vaccines. Um

we also produce eight antigens for IP2

um and IP2 is responsible for um

parasitic vaccines. We produce antigens

for other sites in the MSD network um

that go on to further vaccine

manufacturing and lung. So we do

largecale bacterial vaccines,

parasitics, filling and some secondary

and final packaging here in the UK. So

quite um a big big site um

mostly end to end um and producing here

for the UK and other markets.

So I just wanted to share because

Heptovac always creates the most noise

um because number one it's a mainly

seasonal product and you need it when

you need it which we fully understand um

but wanted to share really the endtoend

lead time for what it takes to create a

single dose of Hepabac. So we get input

from commercial on what they expect that

they will sell. So meaning what you

expect from a total doses requirement.

So we get that and we essentially input

it and we figure out what kind of raw

materials will we need. Um so we go

ahead and we order those and we begin

manufacturing. So some antigens um that

go into Haptivac can be really quite

quick. It can be a month. But several of

the antigens in Hepivvac actually take

about four months to make because

there's a detoxification process that

has to occur and has a specific time

point or a specific reading um for

toxicity that must be hit before we can

move forward in manufacturing. So I

would say manufacturing antigen creates

between one and four months of lead

time. When we look at test and release,

that takes about two and a half months.

And once we get all of the back, all of

the antigens required to make a batch of

heepac, we blend it together. So the

blending and filling is actually one of

the quickest processes,

but then we need to go for QC release.

So testing and a release of filled vials

um takes about five months um just due

to the process of release testing and

then it takes about one and a half

months to pack release distribute get it

in the comms so that you can order it.

So when we look at it that's about 11

and a half months up to 15 months um

that it takes to make the antigens

So, I'm not going to go through too many

details here because um if you're a

fermentation specialist, you might enjoy

talking about processes, but just wanted

to show you a little bit. Um at this um

bottom here, we'll talk about, you know,

we open a seed vial and start to grow

the antigen and it goes in a small

ferment and when it gets to a certain

concentration, we put it in a large

ferment. It goes through a a

clarification step,

a depth filtration step here and then it

goes into our processing vessels which

will be processed through um size

dependent ultra filtration and then

another filtration process and then

sterile filtered. So tiptoail all of the

antigens that go into follow this

process. Um some do go up here for those

detoxification like I shared where it

can be between one and four months that

they sit in those holding vessels uh to

get the correct toxicity level before we

can move on. And then showi which is a

big component of heptivac um goes

through a different process because we

need both the cells and the toxin um to

prevent diseases that go that is also

part of that. So, just a really high

level, but just wanted to show you that

it is when we talk about about one

month. Um, this is all the steps that

it's going through. Um, and those ones

that do go into the detoxification

vessels up here that are, you know, 1 to

four months, once they're detoxified,

then they come down and they follow this process.

process.

So, our fermenters are about 2,000 LERs.

That's our smallest production ferment

to 3,000 L. And all said and done, when

we start with 2 or 3,000 L, we

concentrate it down. And when we get to

this step, these are individual bottles.

These bottles are 40 L. So from 2,000 to

160 L is where we take the antigen that

we need for the vaccine. So you can see

it then becomes quite concentrated and

So just to give you an idea um just some

photos so it kind of helps you imagine

what that looks like on the left hand

side that's the top of our ferment

vessels um so everything is done um

inside the vessel close system um to

ensure that we're hitting GMP manufacturing

manufacturing

um and get a quality product. The middle

is um you see these two rigs at the

back. That's um a depth filtration

system. And then on the right side

you'll see those are those vessels that

I talked about where antigens may wait

um between three and four months for detoxification.

detoxification.

So we will um sample them during that

time, get a result from QC and either

continue to wait or take the next step

into filtering it.

And this is um the filtering process. So

in the middle there you'll see that UF

rig or ultra filtration rig that I

talked about. Um that is a size it's

essentially size exclusion. So we keep

um what we want which is the liquid

portion where the toxin is and we get

rid of the cells. So heac is a bit of an

interesting vaccine because on certain

antigens we want the cells and the toxin

and certain antigens we just want the

toxin or the liquid portion in which the

bacteria has excreted what we're looking

for. And then in the most right hand

picture that is where um two of the

final filtration steps will happen. So

we get um additional uh clarity for the

product through one of them and then the

final one is sterile filtration into the

final container that it'll sit in before

blending. So you can see it is quite um

a long process from a manufacturing standpoint.

standpoint.

And this is just the upstream well call

upstream or antigen manufacturing. It

also has downstream processing with it.

But once the vac or the antigen goes

into that final vessel then it will go

for QC testing and once QC testing is

off then we will be able to move forward

to blending. So

I will explain that process. So one

thing that you may or may not know is

that uh Heptac requires 20 specific

antigens to make the vaccine. So when we

talk about maybe I'll go back to this.

When we talk about this process, we have

to have 20 different batches go through

this same process in order to make one

batch of Heptac. If you want to talk

about Ovivac, um it's the same thing

except we reduce that by three specific

antigens. So OVAC and Heptivvac are very

very close from a a processing

standpoint. OVAC is just a bit simpler.

So as you can see this process is really

complicated um to grow bacteria, clarify

it and uh sterilize it for sterile

vaccine. But we have to do this 20 times

and as you can imagine um things do

happen. Um we might get a lower potency.

So we have minimum potency that we have

to hit by VMD dossier regulations and if

a potency doesn't hit that value that

batch of antigen can't be used. So you

can see how complex um this

manufacturing process is when we have a

20-way vaccine that prevents seven diseases.

diseases.

So once we have the antigen we have all

20 right we're going to take it to the

blending process. Um so Heptivvac

requires Heptovac and OBVAC require um a

precursor blend. Um so we take a vaccine

base and what we do is we add all of

these specific shvi cells and toxin um

to the mix. So there are five different

shvi fractions that go into ovivac and

heepac and we require the cells from

them. So meaning it goes through a

centriuge and we collect all the cells

and then we also collect the toxoid that

goes through that depth filtration and

sterilization process. So we mix both

the cells and the toxin together and we

get what we call a shvi pre-blend. So we

call that an LCAP here. But it's

basically a combination of all the shvi

which is the precursor for making heptac

and ovivback. So once we make that

pre-blend for shvi, we will put it in

sterile bottles and we'll hold it. Um we

need to wait for QC testing. Um and once

the QC testing comes off and tells us

that yes, everything that we put in is

hitting the potency we expect it, it

will give us an output for how strong

this LCAD is and how many doses of

vaccine we can make off of it.

So the next step then is to create a

vaccine base which is essentially your

gel um and and sterile salts. We add the

shvi pre-blend to that and then comes

all of the other antigens. So you can

see here that this is quite a long list

your manheime your hemolyticas your

perringent. So it is quite a list of

additional antigens and a lot of the

antigens they look the same but you'll

see like that A1 A2 A6 those are all

different stereotypes of a specific bacteria

bacteria

so we blend those together

we make a 20-way vaccine

and then it's filled

which we said yeah filling happens in

one day but then the QC testing starts

and the QC testing is roughly between

three and five months. It depends on how

the test goes. Um but quite a a big

piece of the overall puzzle and then

ultimately we can release it and it goes

to comops for vaccination. So um just

really wanted to highlight the

complexity. Um we hear you. Um we we

want to be able to deliver um vaccines

in time um and cover the whole market.

Um but it is quite a specific process in

order to make this specific vaccine. So

I know there are questions about you

know well we make it in the UK but where

does it go? So I also wanted to share

with you um the markets that heavac goes

to and then I also did ovast because um

that just shows you a little bit of a

different flavor. Um, Ovac goes to the

same markets as Heptivvac. Um, so you

look um that obviously we are a UK manufacturer

manufacturer

um really producing majority for the UK

actually UK and Ireland. Um but it is

registered and it does go to other

markets around the world. Um so these um

actually are just a sampling um of the

countries that we serve from the UK. um

our most um most country served by one

product is 27 and that's in our poultry

range. So we also do poultry products um

from Milton Kees as well. So just wanted

to give you a bit of a flavor um of

where these vaccines go um around the

world and what markets are supplied um

locally from Milton Kees. So hope today

was um just maybe a brief overview try

to keep it succinct. could talk about

vaccine manufacturing for quite some

time. Um, but wanted to share with you

uh the labor of love it is for us to get

you the vaccines that you desperately

need. um and really hope that um we can

continue to have that conversation on

what could be better, what could it look

like, and how you can play a part in

giving us, you know, a a good lead time

um and as much information as possible.

So that when you think about that dose

of Heptac that's there, you also know

that we probably produced um all the

antigens for that at least a year ago.

Um in order to do that uh and I wanted

to also share with you that be just

because Heptivvac is a seasonal product

more or less um we are making doses

throughout the entire year um because

the process is so complex and we only

have seven ferment

um at any given time we're making

roughly five batches of antigen a week

that will make its way um to one of your

vaccines. So I really appreciate um the

opportunity to come and and speak with

you speak with you from a a

manufacturing um viewpoint. I know that

it is a frustrating uh situation for you

as a farmer who wants the product. Um

but we are very much aligned with um the

science of healthier animals in doing

what we can do um from a manufacturing

perspective to to make it as easy for

you as possible. So thank you very much Chris.

Chris.

Thanks Rebecca and it's uh thank you

again for joining us today for and for

that presentation. It's not every day we

get to understand the detail and

complexity of the process which goes

into producing the vaccines uh which we

risk taking for granted and uh my my

first point to you is really I think you

should change the name of your title to

vaccine master chef uh because it feels like

>> a bit of a Tetris game for sure.

>> Yeah. Well, you use the word puzzle. I

wrote that down and it is a puzzle,

isn't it? Trying to bring all of these

pieces p pieces together and I think

that's a standout for me that it's a 12

minimum 12 month process for the

vaccines that we want to use at laming

time. You're starting that process a

year ahead. Um I noticed that you you're

sending a lot of your vaccines abroad. Um,

Um,

and and you may not want to answer or be

a be able to answer this question, but

has the has Brexit complicated that

process for you in terms of getting

access out of the country? And I presume

it would be the same for people bringing

things in.

>> Yeah, I mean, it definitely presented a

new opportunity or a new um problem to

solve, right? um as a manufacturer

that's a global manufacturer and

supporting you know really six

continents worth of animals um we

obviously have worked with our our EU

colleagues um at one of our sister sites

to see you know what what would it look

like for us to optimize that right

because um at the beginning of Brexit um

and to this day essentially like any

product going into the EU needs to be

tested in the EU um so we've taken some

of those opportunities to um kind of

have a reciprocity agreement um that

it'll be tested in the EU um and it will

also then be valid for the UK markets.

So essentially um I think everyone saw

the challenges that would arise out of

this decision and it was really you know

how can we work together to make sure

that that doesn't impact the customer.

So, while that was a challenge, um, and

can still be a challenge on certain

things, um, it it doesn't prevent us

from getting you the vaccines that you need,

need,

>> the companies have adjusted and and have

work through those issues. Um, Rebecca,

I just wanted to say, do you want to

click on the um, stop share button just

so that we can bring you unless you had

any other slides you were going to

share. That's it. I can see you.

Brilliant. Um, another tricky one you

may not be able to answer or the the

answer may be very complicated, but our

survey talked about autogenous vaccines

and I know in some sectors uh like the

fish industry, the trout industry for

instance, they're really important

because they they don't have a lot of

antibiotics to use. They don't have a

lot of medicines licensed for fish. But

and and in the back of my head was a

time when you could get I was a sheep

farmer and you could get a CLA vaccine

made for the strain of CLA you had.

How complicated is it? Is that a

realistic thing that we could do that on

any scale? Autotogenous vaccines.

>> So I think so. Autotogenous vaccines

definitely have their time and place in

the market. Um MSD actually does which

is different than autotogenous but does

do some mRNA vaccines in the US. Um

mainly that's around swine and um now

they've launched this year uh companion

animals. So cats and dogs. um similar

but different process than autotogenous.

Um but autotogenous and mRNA vaccines

are really kind of a script vaccine. Um

they don't really hold a large scale

like Heptivvac does, right? So, in some

ways, they're really prohibitive because

you're going to need to have a vet who

does a swab to get it uh genotyped and

then create if it will grow in cells.

Now, not all bacteria will grow in every

cell model. Um, so you do see some

autogenous vaccines um right now for

sale in the US by the USDA. um but is by

veterinary script only and they don't

necessarily guarantee the efficacy. So I

do expect that they will be more

autogenous vaccines and um mRNA vaccines

in the future um but they most likely

won't be at the large scale that we see

heptac because of the unique

kind of herdspecific immunity that

vaccines um usually give.

So the other the other clear thing is

that what the business you're in, your

your plant is clearly not making nuts

and bolts. It's a lovely shiny factory

with the cleaning bill must be a

fortune. Um but but you're not producing

nuts and bolts. It's very it's a very

live process and and I imagine you have

really um strict um protocols and um

operating procedures. But despite all of

the best things that you you alluded to

it in your presentation, things go wrong.

wrong.

Um, again, stating the obvious, this

isn't like a batch of biscuits and you

can sell the broken ones for a knockdown

price or a piece of furniture that's

scrapped and then you put a yellow

sticker on it. If a batch fails, it

fails. It's gone. It's it's in the bin presumably.

presumably.

>> Yeah. I mean, I wish we could. Um but um

you know at any at any part of the good

manufacturing practices um if it doesn't

meet a specification

um it doesn't meet a potency a toxicity

um a quality release test there's no

path forward for it and that really um

it does two things. one, you can say

it's very restrictive, but two, it also

gives you the highest quality product

and you know that what you're getting

meets all of the specifications. So

really that is a consumer protection and

also um a high stamp of quality on any

vaccine that you buy that it has met a

very stringent uh release process and it

is the very best that you can buy.

And and I I heard in your presentation

there that planning is absolutely

paramount to running your plan. Um I

thought of this question before I heard

it was a year-long um leading period. So

probably we can't answer this qu I'm not

quite sure what the answer to this

question is going to be but um from from

the producer end um everything you do is

planned in but obviously you need to

know the eventual demand. you need to

know whether how many vaccines I want.

And uh the the classic one I suppose is

our our deputy chairman who works for

the animal health disease association um

animal health distributors association

would have been chairing this session

today and he uses the classic example of

the farmers runs to his country store

leaves the engine running and he says I

need my vaccine because I've got the

sheep and I want to vaccinate them this

afternoon. That clearly isn't great

planning. Um, but I'm not quite sure how

we can give you 12 months notice. That's

going to require more kind of strategic

planning from the likes of AHDB, etc.

>> So, absolutely right. Um, we can't react

to huge market swings. What we can do

though is we can work with our

commercial colleagues that give us a

sales forecast where essentially that's

market research. That's talking to um

distributors and farmers um on what they

project that they're going to use. They

compile all that information and they

give us a year looking forward where

they believe, you know, based on

experience, based on the data they have

on hand, and based on kind of

probabilities and statistics, how many

doses they think they can sell, right?

So, they're held to the account of how

many doses they think they can sell. we

translate that into how many doses we

can make and the hard part is does it

get to the shelf um on the day that that

farmer wants the vaccine. So it it does

it is a complicated process. um there is

area for opportunity, but I think um

what we would ask then is you work with

like your vette, your your local

conglomerate that you work together um

to really be a voice for how much of

that vaccine do you think you're going

to have? How has your herd changed over

the years? Where are you going, right?

to get as much information um through

the commercial chain so that they can

give us their projected projections and

we can work um on what we can do to meet

that demand. Um so we can't change

quickly but we're always producing right

so it's not like we just start every

year the year just never stops for us.

So um that 12 month lead time really is

if I started today, right? So all every

day we're making antigens that will go

into a vaccine. So we're not starting at

the 11 and a half month point. We're

starting for some vaccines at the the

antigen point. Maybe we need one or two

batches of antigen and we go then

forward to blending. So it while it is a

long lead time um and that is the pace

of it there is opportunity in the small

sense for the better we know the better

we can do.

>> Uh I want to call the Q&A to to an end

because we need to move on but I just

wanted to to to make that point clear. I

think that's certainly something I take

out of this that the planning if the

more we can do from the the user end to

support manufacturers with that

information the better and you talk

about opportunities and that kind of

leads us into the next session of our

webinar really nicely the opportunities

for how we try and address this issue

and it it's not about pointing fingers

at anyone particular it's about how we

can all come together to try and make

the the the availability and supply of

vaccines better so Becky I just want to

thank you very partnership. Not every

day we get an opportunity to see inside

your world, but thanks for sharing that

with us and uh please stay with us for

the rest of the webinar if you have time.

time.

>> Yeah, thanks Chris.

>> Thank you. So, um that that takes us on

to the sort of uh the final section of

our webinar really. And Rumor and its

alliance members have been sharing their

concerns about vaccine availability with

the VMD over the last couple of years.

and via a series of workshops the EMD

organized they've listened to those concerns

concerns

we all understand the issues is

complicated and we've just talked about

the man manufacturing side of it but

there are more complications than that

but that doesn't mean we can't try to

improve the situation so rumor was

really pleased to see the statement of

intent announced by the VMD in September

of this year

unfortunately those involved from senior

level at the VMD were unable to attend

the webinar on the day that we set it

because of diary clashes, but they were

keen to be involved. And so we recorded

a presentation which shares details

about the government's response uh to

our concerns over availability which was

set out in the in September's statement

of intent. So this presentation is by

Cla Stratford. She's the principal

veterary adviser to the VMD and as I

said earlier on, she's head of research,

innovation, sustainability, and evidence

at the VMD.

Mary, could I ask you to uh play CLA's

recording presentation?

>> Yes, I can.

>> Recorded presentation.

>> I can just to say to everyone, the sound

um the sound is on slightly on the low

side on on CLA's recording. So, please

do make sure that you've got your um

your own microphone microphones as high

as you um can take them. So, I'll get

Is that coming through Chris?

>> I can see it but I can't hear it. Best

laid plans of mice and men.

health industry to better understand the

vaccine availability issues that the UK

market has been facing and to develop a

strategic approach to start to

In this short presentation, I will cover

the background and engagement activities

that led to this UK veterary vaccine

availability initiative, the recent

publication of the statement of intent

on UK veterary vaccine availability, and

a summary of the contents of this

statement and the proposed strategic

framework for action and the next steps

to develop a multistakeholder UK action

So starting with the background that led

to and informed the statement of intent,

concerns regarding vaccine availability

were initially raised by the sheep

sector which led to the BMD convening

the first vaccine roundt discussions in

November of 2023.

This meeting led to further engagement

activities with wider stakeholders from

different sectors, including surveying

marketing authorization holders to

understand the extent and causality of

any supply issues with their vaccines.

Meetings with representatives from

different species groups with regulators

from other countries and with government

colleagues to understand related

activities and opportunities.

From these activities, we gained a

better understanding of the landscape

and it became clear that vaccine

availability was a wider problem than

impacting just the sheep sector, instead

impacting multiple species and multiple

sector groups. The VMD therefore

convened a second round table in

February of this year with wider

stakeholder representation

and the aim of this second round table

was to agree the key issues and promote

co-ownership of solutions from across

the animal health sector recognizing

that we need collaborative activity

across the sector to address what we

recognize as a multifaceted problem. At

this second round table, we collected

potential solutions and commitments to

inform the next steps and there was

collective enthusiasm for some form of

multistakeholder national strategy or

action plan which the BMD agreed to

champion and coordinate.

So from here we collected all the

information and feedback from these

engagement activities and proposed what

we termed a strategic framework for

action. We then sense checked this with

stakeholders from across industry and

government at a series of workshops in

May. This then informed the drafting and

content of the statement of intent on UK

veterary vaccine availability which

following the appropriate ministerial

clearances was published on gov.uk in

And here is a screenshot of this

statement of intent on UK veterary

vaccine availability which was published

as a policy paper on gov.uk and you can

find the associated web address at the

bottom of the screen. We're delighted to

have received support for this work from

Baroness Hmon as can be seen in the

We believe that the statement of intent

has been received positively and we're

very grateful to all the organizations

that helped amplify the message and the

publication via their own communication

channels as you can see from some of the

So for those that haven't yet had chance

to read the document in any detail, what

is the statement of intent? Essentially,

the statement of intent is a document

authored by the VMD, but reflecting all

the feedback and information we've

received from our engagement activities

across the animal health sector. It

details what we understand about current

vaccine availability issues and how we

hope to address these in a collaborative

way working with stakeholders from

across the sector.

It outlines the need for veterary

vaccines, the concerns over vaccine

availability, the longerterm vision for

future vaccine availability, and

importantly describes this strategic

framework for multistakeholder action

and what the next steps are to develop

an associated national action plan. The

aim of this statement of intent is to

show the required direction of travel

for future action to signal intent

foster collaboration and act as an

impetus for the wide cross- sector

engagement that is required for success.

And I'll now provide an overview of each

So firstly looking at the need for

veterary vaccines which I'm sure is

really clear for everyone on this call

but obviously vaccines are essential

tools to protect animal health and

welfare and in doing so they underpin

livestock productivity food production

food security and both the farming and

the wider economy. They also help

protect public health for example by

reducing the risk of transmission of

some zunotic diseases from animals to

humans. and they're a really important

part of our antimicrobial stewardship

toolkit, helping us in our onehealth

efforts to reduce antimicrobial usage to

minimize the development and spread of

antimicrobial resistance.

On top of this, we expect our need for

veterary vaccines to grow, for example,

due to new disease incursions secondary

to climate change, which we've seen

recently with blue tongue, and risks

posed by increasing global movement of

people, animal, and animal products. And

importantly, we've also witnessed the

negative impacts of lack of a vaccine

availability, many of which are reported

in the rumor vaccine survey that you've

heard more about this morning. And not

least, the negative impacts on farmer

and vet well-being was seeing disease in

their stock that could potentially have

been prevented if appropriate vaccines

Moving next to the concerns over vaccine

availability, it's important first to

recognize that vaccine production is a

very complex biological process with

multiple points of potential failure and

multiple interconnected influencing

factors that can determine the

availability or uptake of a particular

vaccine. And this diagram depicts this

complicated process from initial vaccine

research and development through product

authorization, manufacture and then

distribution to wholesale, then

prescription and finally use in an

animal. In addition, often supply chains

for veterary vaccines involve multiple

different countries with different

stages of manufacture and packaging

happening in different countries and the

final product is often intended to serve

several different markets.

On top of this, there are various

potential influencing factors seen in

the green circle that can affect

availability and uptake of a vaccine.

And these include social and economic

influences, disease pressures, competing

demands, trade agreements, and usage policies.

policies. I think it's important that we keep in

I think it's important that we keep in mind how complicated this is and that

mind how complicated this is and that there are different nuances for each

there are different nuances for each indiv individual vaccine that we have on

indiv individual vaccine that we have on the market. meaning that different

the market. meaning that different vaccine availability issues may require

vaccine availability issues may require different solutions. We also know from

different solutions. We also know from our engagement with colleagues in other

our engagement with colleagues in other countries that the UK is not alone in

countries that the UK is not alone in facing vaccine availability issues and

facing vaccine availability issues and that many of these challenges are felt

that many of these challenges are felt globally.

Our stakeholder engagement identified two key issues. Firstly, supply not

two key issues. Firstly, supply not meeting demand for some existing

meeting demand for some existing vaccines and a number of people watching

vaccines and a number of people watching today's webinar will have been directly

today's webinar will have been directly impacted by this. And secondly,

impacted by this. And secondly, stakeholders reported concerns over a

stakeholders reported concerns over a potential lack of development and

potential lack of development and innovation of new vaccines to fill

innovation of new vaccines to fill existing and emerging therapeutic gaps.

existing and emerging therapeutic gaps. The statement of intent then goes on to

The statement of intent then goes on to describe how the veterary medicine

describe how the veterary medicine sector in the UK is a private industry

sector in the UK is a private industry in which developing and bringing

in which developing and bringing vaccines to the market is a commercial

vaccines to the market is a commercial decision and there is a complex

decision and there is a complex interplay where adequate uptake of

interplay where adequate uptake of vaccines is required to generate

vaccines is required to generate sufficient market pull to incentivize

sufficient market pull to incentivize industry to manufacture these products.

industry to manufacture these products. So we need uptake to promote ail

So we need uptake to promote ail availability

availability but we also know that lack of

but we also know that lack of availability in turn leads to reduced

availability in turn leads to reduced vaccine uptake and a lack of confidence

vaccine uptake and a lack of confidence in purchase. So there's a need for us to

in purchase. So there's a need for us to think more here about how we can start

think more here about how we can start to better demonstrate the potential

to better demonstrate the potential market for these vaccines in the UK to

market for these vaccines in the UK to promote availability.

promote availability. Then there's a description of existing

Then there's a description of existing national and regional efforts to promote

national and regional efforts to promote vaccine availability that are already

vaccine availability that are already underway to describe the existing

underway to describe the existing landscape of activities that future work

landscape of activities that future work should attempt to amplify and build on.

Moving on to the wider vision, we need safe, effective vaccines available at

safe, effective vaccines available at the right time to prevent disease in our

the right time to prevent disease in our animal population and minimize use of

animal population and minimize use of antimicrobials.

antimicrobials. The statement of intent aims to

The statement of intent aims to illustrate how work by stakeholders from

illustrate how work by stakeholders from across the animal health sector in the

across the animal health sector in the short to medium term will help make

short to medium term will help make progress towards this wider ambition by

progress towards this wider ambition by establishing and supporting

establishing and supporting multistakeholder networks both

multistakeholder networks both nationally and internationally to

nationally and internationally to enhance awareness and oversight of

enhance awareness and oversight of vaccine availability issues. By

vaccine availability issues. By improving our communication mechanisms

improving our communication mechanisms regarding when supply will not meet

regarding when supply will not meet forecast demand, particularly for what

forecast demand, particularly for what we consider to be critical vaccines. By

we consider to be critical vaccines. By promoting fair distribution and uptake

promoting fair distribution and uptake of available products and supporting

of available products and supporting sourcing of alternatives where

sourcing of alternatives where appropriate.

appropriate. By stimulating innovation to support the

By stimulating innovation to support the pipeline of new products and

pipeline of new products and technologies to address current

technologies to address current challenges and new disease threats. and

challenges and new disease threats. and by better understanding the current

by better understanding the current manufacturing landscape and identifying

manufacturing landscape and identifying any potential opportunities for future

any potential opportunities for future growth or diversification.

So then moving on to how stakeholders might realize this ambition. The

might realize this ambition. The statement of intent proposes a strategic

statement of intent proposes a strategic framework for multistakeholder action

framework for multistakeholder action with activities divided into four

with activities divided into four interconnected strategic themes which

interconnected strategic themes which are improve supply and uptake, support

are improve supply and uptake, support innovation, review the manufacturing

innovation, review the manufacturing landscape, and underpinning all of these

landscape, and underpinning all of these the theme of working in partnership. And

the theme of working in partnership. And you'll see that there are various

you'll see that there are various proposed work streams under each of

proposed work streams under each of these themes. many of which start with

these themes. many of which start with addressing knowledge gaps. Our research

addressing knowledge gaps. Our research and engagement activities so far have

and engagement activities so far have generated a lot of information regarding

generated a lot of information regarding the current vaccine landscape, but we

the current vaccine landscape, but we still need further detail in some areas

still need further detail in some areas to ensure that we direct our future

to ensure that we direct our future activities appropriately.

activities appropriately. So just to provide a little flavor of

So just to provide a little flavor of the suggested work streams and

the suggested work streams and activities under each of these strategic

activities under each of these strategic themes, the improved supply and uptake

themes, the improved supply and uptake theme aims to use improved communication

theme aims to use improved communication to mitigate supply issues for existing

to mitigate supply issues for existing products whilst also laying the

products whilst also laying the foundations for more resilient and

foundations for more resilient and transparent supply and uptake of future

transparent supply and uptake of future products.

products. and suggested work streams include

and suggested work streams include addressing knowledge gaps by research to

addressing knowledge gaps by research to better understand the causes and scale

better understand the causes and scale of existing supply issues. Another

of existing supply issues. Another important activity will be to work with

important activity will be to work with sector groups to define and agree

sector groups to define and agree critical vaccines i.e. vaccines for

critical vaccines i.e. vaccines for which we consider shortages to be of

which we consider shortages to be of greatest significance. And this will

greatest significance. And this will help us refine our activities so that we

help us refine our activities so that we can concentrate our forecasting,

can concentrate our forecasting, communication and mitigation activities

communication and mitigation activities on these prioritized critical vaccines.

on these prioritized critical vaccines. Other work streams include looking at

Other work streams include looking at potential opportunities to safeguard

potential opportunities to safeguard supply, for example, by requiring the

supply, for example, by requiring the provision of shortage and mitigation

provision of shortage and mitigation plans. They also include facilitating

plans. They also include facilitating the sourcing of alternative products

the sourcing of alternative products where appropriate, for example, via the

where appropriate, for example, via the special import scheme and the autogenous

special import scheme and the autogenous vaccine authorization or AVA provisions.

vaccine authorization or AVA provisions. And looking at ways that we can

And looking at ways that we can demonstrate an enhanced market pull to

demonstrate an enhanced market pull to provide confidence to pharmaceutical

provide confidence to pharmaceutical companies that they can achieve

companies that they can achieve sufficient return on investment. And

sufficient return on investment. And it's hoped that the work streams and

it's hoped that the work streams and activities under this improved supply

activities under this improved supply and uptake theme will improve stock

and uptake theme will improve stock control of existing products in the

control of existing products in the short term and that this work will be

short term and that this work will be complemented by work to augment the

complemented by work to augment the pipeline of new product innovation and

pipeline of new product innovation and manufacture from the support innovation

manufacture from the support innovation and review manufacturing landscape

and review manufacturing landscape themes.

themes. So the support innovation theme aims to

So the support innovation theme aims to facilitate the pipeline of new products

facilitate the pipeline of new products required to address new and emerging

required to address new and emerging therapeutic gaps and suggested work

therapeutic gaps and suggested work streams include bridging the gap between

streams include bridging the gap between end users and innovators and funders by

end users and innovators and funders by working to identify our market needs and

working to identify our market needs and then communicating these to innovators

then communicating these to innovators and funders to stimulate investment in

and funders to stimulate investment in associated vaccine recent research and

associated vaccine recent research and development. Other work streams include

development. Other work streams include ensuring that our regulatory framework

ensuring that our regulatory framework continues to support innovation of new

continues to support innovation of new products and technologies whilst

products and technologies whilst providing the necessary safeguards of

providing the necessary safeguards of quality, safety, and efficacy.

quality, safety, and efficacy. The review manufacturing landscape theme

The review manufacturing landscape theme aims to evaluate current UK vaccine

aims to evaluate current UK vaccine manufacturing capability and capacity

manufacturing capability and capacity and potential opportunities for

and potential opportunities for longerterm growth to support more

longerterm growth to support more resilient and responsive future vaccine

resilient and responsive future vaccine production. And it will also look to

production. And it will also look to identify potential future alignment

identify potential future alignment opportunities with human vaccine

opportunities with human vaccine research and manufacturing and

research and manufacturing and understand the benefits and risks to

understand the benefits and risks to such an approach.

such an approach. And these themes are underpinned by the

And these themes are underpinned by the need to work in partnership with

need to work in partnership with stakeholders both nationally and

stakeholders both nationally and internationally to promote awareness of

internationally to promote awareness of the issue, collaboration, action, and

the issue, collaboration, action, and global influence. And the first major

global influence. And the first major activity under this work in partnership

activity under this work in partnership theme is to translate all of these

theme is to translate all of these suggested work streams and activities

suggested work streams and activities into a detailed five-year

into a detailed five-year multistakeholder UK action plan.

So this takes me nicely onto my next slide in terms of next steps and you can

slide in terms of next steps and you can see where we are in the process to date.

see where we are in the process to date. So we've been through the collect

So we've been through the collect information and engage phase to

information and engage phase to publishing of the statement of intent

publishing of the statement of intent and we're currently in a new phase of

and we're currently in a new phase of multistakeholder engagement convening

multistakeholder engagement convening representatives from across the

representatives from across the pharmaceutical industry including um

pharmaceutical industry including um distributors, prescribers and suppliers

distributors, prescribers and suppliers of medicines, government farming and

of medicines, government farming and companion animal groups with the aim to

companion animal groups with the aim to determine the process through which this

determine the process through which this 5-year multistakeholder UK action plan

5-year multistakeholder UK action plan will be developed, governed and

will be developed, governed and implemented with the aim to publish this

implemented with the aim to publish this action plan within within the next year.

action plan within within the next year. So, in terms of developing the action

So, in terms of developing the action plan, as I've stated, our aim is to

plan, as I've stated, our aim is to develop and publish a 5-year action plan

develop and publish a 5-year action plan by September of 2026. And the VMD will

by September of 2026. And the VMD will be working to champion and coordinate

be working to champion and coordinate this action plan development alongside

this action plan development alongside our existing regulatory functions. And

our existing regulatory functions. And it's important to recognize that success

it's important to recognize that success can't be achieved by the VMD alone, and

can't be achieved by the VMD alone, and that this will require active

that this will require active participation from stakeholders from

participation from stakeholders from across the animal health sector. Our

across the animal health sector. Our next activities are therefore to

next activities are therefore to encourage this multis- sector

encourage this multis- sector participation in development and

participation in development and delivery of the action plan. This means

delivery of the action plan. This means putting concrete activities with clear

putting concrete activities with clear timelines, endpoints and owners to the

timelines, endpoints and owners to the work streams and strategic themes I've

work streams and strategic themes I've just discussed. And we're actively

just discussed. And we're actively seeking feedback to help shape these

seeking feedback to help shape these next steps of action plan governance and

next steps of action plan governance and development. We hosted a workshop with

development. We hosted a workshop with industry representatives in mid-occtober

industry representatives in mid-occtober who largely supported our proposed

who largely supported our proposed approach to action plan development with

approach to action plan development with a few tweaks and we're planning similar

a few tweaks and we're planning similar meetings across government and with

meetings across government and with academia and researchers to also get

academia and researchers to also get their feedback.

So now talking you through our proposed approach to action plan development and

approach to action plan development and delivery. Firstly thinking about the

delivery. Firstly thinking about the governance or oversight of the action

governance or oversight of the action plan. Our proposal is that this is

plan. Our proposal is that this is provided by an advisory group made up of

provided by an advisory group made up of invited independent key opinion leaders

invited independent key opinion leaders from across the animal health sector. So

from across the animal health sector. So including research, government,

including research, government, manufacturers, representatives from the

manufacturers, representatives from the distribution chain, vets and animal

distribution chain, vets and animal keepers with the idea that this small

keepers with the idea that this small group would help provide strategic input

group would help provide strategic input into the direction and priorities of

into the direction and priorities of this vaccine availability initiative and

this vaccine availability initiative and really importantly link this work into

really importantly link this work into the wider landscape of animal and one

the wider landscape of animal and one health strategies and plans and

health strategies and plans and potential funding sources. We also see

potential funding sources. We also see that this advisory group playing a key

that this advisory group playing a key role in championing the action plan and

role in championing the action plan and its activities, making sure that

its activities, making sure that information is disseminated widely. We

information is disseminated widely. We haven't landed on the exact number, but

haven't landed on the exact number, but we envisionage having about 12

we envisionage having about 12 individuals on this group and that the

individuals on this group and that the group would meet a couple of times a

group would meet a couple of times a year, probably more frequently than that

year, probably more frequently than that in the early stages.

in the early stages. Moving

Moving on to the content of the action plan

on to the content of the action plan itself for the supply innovate and

itself for the supply innovate and manufacture themes. We envision

manufacture themes. We envision facilitating one or more workshops per

facilitating one or more workshops per theme over the next six to eight months

theme over the next six to eight months involving the wider spectrum of

involving the wider spectrum of stakeholders who are prepared and able

stakeholders who are prepared and able to commit to supporting action plan

to commit to supporting action plan development and delivery. And the

development and delivery. And the purpose of these workshops will be to

purpose of these workshops will be to tease out the exact activities,

tease out the exact activities, deliverables, timelines and ownership

deliverables, timelines and ownership that will be detailed in the action

that will be detailed in the action plan. And we can have as many of these

plan. And we can have as many of these workshops as needed and we'll try to do

workshops as needed and we'll try to do them as flexibly as we can. We then

them as flexibly as we can. We then envision there being an action plan

envision there being an action plan working group which would then act as a

working group which would then act as a driver for tracking and reporting

driver for tracking and reporting against these agreed activities within

against these agreed activities within the action plan and representatives on

the action plan and representatives on that will act as points of contact for

that will act as points of contact for their sectors both gathering and

their sectors both gathering and disseminating information.

disseminating information. We envisaged that this working group

We envisaged that this working group would meet three to four times a year

would meet three to four times a year but again potentially more in the

but again potentially more in the initial phases of action plan

initial phases of action plan development.

In addition to this for the supply theme we're envisaging establishing what we're

we're envisaging establishing what we're terming a stakeholder dialogue platform

terming a stakeholder dialogue platform basically a mechanism of connecting

basically a mechanism of connecting stakeholders and the purpose of this

stakeholders and the purpose of this will be to specifically focus on

will be to specifically focus on enhancing communication and sharing of

enhancing communication and sharing of intelligence regarding the supply chain.

intelligence regarding the supply chain. We can use it to help de develop and

We can use it to help de develop and agree mitigations to issues that have

agree mitigations to issues that have arisen or are anticipated and to help

arisen or are anticipated and to help agree what information needs to be

agree what information needs to be disseminated and where. So we see it

disseminated and where. So we see it both as a source of intelligence that

both as a source of intelligence that would also inform some of the action

would also inform some of the action plan development and delivery but also

plan development and delivery but also as a means to address and mitigate

as a means to address and mitigate specific supply issues.

specific supply issues. In addition to these structures, we

In addition to these structures, we envision hosting annual stakeholder

envision hosting annual stakeholder information and networking events where

information and networking events where updates on action plan delivery will be

updates on action plan delivery will be presented and there'll be an opportunity

presented and there'll be an opportunity for discussion and feedback on the

for discussion and feedback on the challenges that have been experienced

challenges that have been experienced and on opportunities that have arisen.

and on opportunities that have arisen. In addition, we hope to create a

In addition, we hope to create a SharePoint site or similar which will

SharePoint site or similar which will enable us to host resources and

enable us to host resources and disseminate relevant information that

disseminate relevant information that will be accessible to all those people

will be accessible to all those people who are participating or who have

who are participating or who have registered an active interest in this

registered an active interest in this vaccine initiative.

vaccine initiative. So, this is our initial start of a 10 of

So, this is our initial start of a 10 of the proposed approach and we're actively

the proposed approach and we're actively seeking feedback on it. Now, you'll

seeking feedback on it. Now, you'll notice I haven't specifically mentioned

notice I haven't specifically mentioned the working in partnership theme, but we

the working in partnership theme, but we see that as being embedded in what we're

see that as being embedded in what we're doing now and through the process that

doing now and through the process that we're developing. The VMD have agreed to

we're developing. The VMD have agreed to coordinate and champion this work, but

coordinate and champion this work, but as stated before, the success of the

as stated before, the success of the initiative will be dependent upon action

initiative will be dependent upon action from all impacted stakeholders. We've

from all impacted stakeholders. We've already invited industry organizations

already invited industry organizations to start to consider which workshops or

to start to consider which workshops or groups that they might wish to be part

groups that they might wish to be part of and have started to collect a straw

of and have started to collect a straw poll of that information. And over the

poll of that information. And over the next month, we'll be reaching out

next month, we'll be reaching out individually to those organizations to

individually to those organizations to get further information regarding their

get further information regarding their potential involvement.

So just looking at that pictorially now you'll see that the first activities

you'll see that the first activities will be to establish the advisory group

will be to establish the advisory group and to run the supply innovation and

and to run the supply innovation and manufacturing planning workshops. These

manufacturing planning workshops. These in turn will inform the development of

in turn will inform the development of the action plan working group and the

the action plan working group and the stakeholder dialogue platform with the

stakeholder dialogue platform with the aim to publish the action plan in

aim to publish the action plan in September of 2026.

September of 2026. The advisory and working groups and

The advisory and working groups and stakeholder dialogue platform will

stakeholder dialogue platform will continue through the five-year life plan

continue through the five-year life plan of action plan delivery and alongside

of action plan delivery and alongside those of the proposed annual stakeholder

those of the proposed annual stakeholder events which will form just one part of

events which will form just one part of a wider communication initiative.

And finally, whilst all of that planning is happening over the next 12 months, I

is happening over the next 12 months, I think it's important to stress that we

think it's important to stress that we recognize that some people are facing

recognize that some people are facing live vaccine supply issues now and that

live vaccine supply issues now and that alongside the action plan development

alongside the action plan development activities, there's a need for some work

activities, there's a need for some work to commence immediately in parallel.

to commence immediately in parallel. Some such activities are already

Some such activities are already happening and we're really grateful for

happening and we're really grateful for the rumor of vaccine surveys, both the

the rumor of vaccine surveys, both the agriculture survey that you've heard

agriculture survey that you've heard more about today and the companion

more about today and the companion animal and equin one. Both of which seek

animal and equin one. Both of which seek to better understand vaccine supply

to better understand vaccine supply issues and impacts. From a VMD

issues and impacts. From a VMD perspective, alongside our action plan

perspective, alongside our action plan coordination activities, we're

coordination activities, we're undertaking and looking to commission

undertaking and looking to commission research to address some of the

research to address some of the knowledge gaps I've spoken about. We'll

knowledge gaps I've spoken about. We'll be better utilizing the new legislative

be better utilizing the new legislative requirement for pharmaceutical companies

requirement for pharmaceutical companies to report national shortages to us. And

to report national shortages to us. And we'll be issuing communications to

we'll be issuing communications to clarify opportunities for use of

clarify opportunities for use of alternative products where supply issues

alternative products where supply issues exist. For example, by utilizing the

exist. For example, by utilizing the special import scheme or AVA provisions.

special import scheme or AVA provisions. And we hope to see similar parallel

And we hope to see similar parallel activities happening across the wider

activities happening across the wider animal health sector. And we'll look to

animal health sector. And we'll look to how these activities can be best

how these activities can be best communicated to demonstrate progress.

communicated to demonstrate progress. So that's been a bit of a whistle stop

So that's been a bit of a whistle stop tour of the statement of intent and our

tour of the statement of intent and our vaccine availability initiative, but I

vaccine availability initiative, but I hope it gives a flavor of the work to

hope it gives a flavor of the work to date and the intended direction of

date and the intended direction of travel. I'd like to acknowledge the

travel. I'd like to acknowledge the organizations on this slide who all had

organizations on this slide who all had representatives that participated in the

representatives that participated in the engagement activities that informed and

engagement activities that informed and discussed the statement of intent. And

discussed the statement of intent. And hopefully those on the webinar today can

hopefully those on the webinar today can recognize organizations here that they

recognize organizations here that they are members of and through whom they may

are members of and through whom they may wish to participate in this work as it

wish to participate in this work as it moves forward.

moves forward. Finally, in summary, we recognize and

Finally, in summary, we recognize and understand the concerns regarding

understand the concerns regarding vaccine availability which have led to

vaccine availability which have led to this new national veterary vaccine

this new national veterary vaccine availability initiative. We see the

availability initiative. We see the publication of the statement of intent

publication of the statement of intent as an important step forward. The next

as an important step forward. The next step will be to capitalize on the

step will be to capitalize on the momentum as we start to build the action

momentum as we start to build the action plan over the next 12 months. also with

plan over the next 12 months. also with those ongoing parallel activities to

those ongoing parallel activities to address some of the more pressing

address some of the more pressing current issues. I've highlighted that

current issues. I've highlighted that this is a complicated process and that

this is a complicated process and that success will be dependent upon

success will be dependent upon multistakeholder input and

multistakeholder input and communication. We're very much in the

communication. We're very much in the early stages of this work. So the

early stages of this work. So the proposed approach I've presented is very

proposed approach I've presented is very much a start of a 10 and will be subject

much a start of a 10 and will be subject to change as the process moves forward

to change as the process moves forward and evolves. We would very much welcome

and evolves. We would very much welcome any feedback and I understand that rumor

any feedback and I understand that rumor is kindly going to collect any feedback

is kindly going to collect any feedback from this webinar and send it to us.

from this webinar and send it to us. Hopefully you'll understand that we're

Hopefully you'll understand that we're not in a position to respond

not in a position to respond individually to feedback but are always

individually to feedback but are always grateful for such feedback and can

grateful for such feedback and can assure you that it will be taken into

assure you that it will be taken into consideration as we progress with this

consideration as we progress with this initiative. Thank you very much for your

initiative. Thank you very much for your time.

>> Thanks. So Mary, if you can um so that was recorded a couple of weeks ago and

was recorded a couple of weeks ago and we um we also recorded a a Q&A. Um

we um we also recorded a a Q&A. Um obviously they were only the questions

obviously they were only the questions which I we we thought of we we haven't

which I we we thought of we we haven't got live we didn't have a live audience

got live we didn't have a live audience but I think I've seen one of the

but I think I've seen one of the questions in the Q&A that we've had

questions in the Q&A that we've had today about getting to the bottom of why

today about getting to the bottom of why this has become more of an issue. And I

this has become more of an issue. And I I think you can see from the breadth and

I think you can see from the breadth and scope of the proposed action plan that

scope of the proposed action plan that this is intending to get to the bottom

this is intending to get to the bottom of why this has become more of an issue

of why this has become more of an issue in recent years. But not just why but

in recent years. But not just why but also to try and deal with the pinch

also to try and deal with the pinch points that uh that process identifies.

points that uh that process identifies. I think what also comes out the

I think what also comes out the presentation it's clear this has to be a

presentation it's clear this has to be a team effort right across the industry

team effort right across the industry from um government manufacturers

from um government manufacturers stakeholder organizations farmers vets.

stakeholder organizations farmers vets. we all need to play a part to contribute

we all need to play a part to contribute our ideas to contribute what we can in

our ideas to contribute what we can in terms of better communication and so on

terms of better communication and so on and the VMD are very open as there was a

and the VMD are very open as there was a list of organizations there and CLA made

list of organizations there and CLA made the point that you should be able to see

the point that you should be able to see something an organization you're

something an organization you're connected to but if you feel you've got

connected to but if you feel you've got something to offer this process the VMD

something to offer this process the VMD are very open to um uh organizations or

are very open to um uh organizations or individuals um signing up so if you

individuals um signing up so if you haven't registered your interest uh

haven't registered your interest uh Please do so. You can do that through

Please do so. You can do that through rumor by contacting me, contacting us.

rumor by contacting me, contacting us. I'm happy to forward that on. If you

I'm happy to forward that on. If you have any questions, as CLA said, uh, put

have any questions, as CLA said, uh, put them in the Q&A and we'll happily pass

them in the Q&A and we'll happily pass them on. So, Mary, have you got the Q&A

them on. So, Mary, have you got the Q&A bit lined up?

bit lined up? We'll we'll move to that then. Thank

We'll we'll move to that then. Thank you.

you. >> I have Chris. Just bear with me one

>> I have Chris. Just bear with me one minute.

So, um, welcome to this, uh, pre-recorded Q&A on vaccines. And I'm

pre-recorded Q&A on vaccines. And I'm delighted to be uh joined today by

delighted to be uh joined today by Claire Stratford who's principal

Claire Stratford who's principal veterary adviser at the VMD and Suzanne

veterary adviser at the VMD and Suzanne Ecford who is head of international

Ecford who is head of international office at VMD who and they are both

office at VMD who and they are both co-steering the VMD's um activity on the

co-steering the VMD's um activity on the vaccine availability initiative. Thanks

vaccine availability initiative. Thanks for joining me today and um apologies we

for joining me today and um apologies we couldn't have you on live but understand

couldn't have you on live but understand one's not in the country and the other

one's not in the country and the other person had already been pre-arranged

person had already been pre-arranged when we chose the date. So great to have

when we chose the date. So great to have you here today. Claire, that was a great

you here today. Claire, that was a great presentation and I think that takes us

presentation and I think that takes us through the the detail of the statement

through the the detail of the statement intend and the the activity that will

intend and the the activity that will happen. But I just wanted to acknowledge

happen. But I just wanted to acknowledge really on behalf of the industry our

really on behalf of the industry our gratitude to the VMD for listening. So

gratitude to the VMD for listening. So there's been um uh the industry's come

there's been um uh the industry's come to you with a problem and I think this

to you with a problem and I think this is a great example of the government and

is a great example of the government and industry working together. We shared our

industry working together. We shared our concerns. You've listened to them and

concerns. You've listened to them and that is really where the statement of

that is really where the statement of intent came from. And I I can certainly

intent came from. And I I can certainly speak on behalf of Rumor Agriculture and

speak on behalf of Rumor Agriculture and I think also Rumor Companion Animal and

I think also Rumor Companion Animal and Equin, our sister organization in the

Equin, our sister organization in the companion animal world. We're we're keen

companion animal world. We're we're keen to work with you in any way we can to um

to work with you in any way we can to um as I'm sure other elements of the

as I'm sure other elements of the industry are to try and make the best of

industry are to try and make the best of what we can out of this initiative.

what we can out of this initiative. There is a problem. We all know it's

There is a problem. We all know it's complicated, really complicated.

complicated, really complicated. So, it's not a given that there will be

So, it's not a given that there will be a successful outcome to this. We all

a successful outcome to this. We all have to join and and participate in

have to join and and participate in that. So, hopefully that sets us up for

that. So, hopefully that sets us up for some of the questions. And I really just

some of the questions. And I really just wanted to having seen the presentation,

wanted to having seen the presentation, having been involved in some of the kind

having been involved in some of the kind of more kind of intimate workshops that

of more kind of intimate workshops that you've held, I think it would just be

you've held, I think it would just be useful to share some of the detail with

useful to share some of the detail with the with our wider audience today. So um

the with our wider audience today. So um can you talk us through the time frame

can you talk us through the time frame for the um vaccine availability

for the um vaccine availability initiative? You you've outlined some of

initiative? You you've outlined some of the steps there and some of the detail,

the steps there and some of the detail, but could you talk us through some of

but could you talk us through some of the timeline?

the timeline? >> Sure. I'll kick off with this one. Um so

>> Sure. I'll kick off with this one. Um so I think we're at the start of the

I think we're at the start of the journey. It's the early days. Um but as

journey. It's the early days. Um but as CLA's outlined in the presentation um

CLA's outlined in the presentation um this stage we're at currently is um all

this stage we're at currently is um all about getting uh lots of stakeholder

about getting uh lots of stakeholder input into the whole process of

input into the whole process of developing an action plan and we

developing an action plan and we envision that taking place over the next

envision that taking place over the next 12 months with a to kind of publish

12 months with a to kind of publish around about September 26 of next year

around about September 26 of next year and following that we envision those

and following that we envision those activities that have been kind of put in

activities that have been kind of put in place in the action plan to take place

place in the action plan to take place over the following five years. So, we're

over the following five years. So, we're looking at a six-year process for

looking at a six-year process for timeline for this initiative. Um, but I

timeline for this initiative. Um, but I just want to kind of bring another angle

just want to kind of bring another angle to that because, you know, that feels

to that because, you know, that feels like a really long time. You say six

like a really long time. You say six years and you know, you've heard Chris

years and you know, you've heard Chris and we certainly hear that people are

and we certainly hear that people are saying right now we've got some problems

saying right now we've got some problems with vaccines. Um, so I guess just to

with vaccines. Um, so I guess just to reassure this isn't a case of we're just

reassure this isn't a case of we're just sitting doing um thinking caps on for 12

sitting doing um thinking caps on for 12 months before anything starts. um some

months before anything starts. um some of those live current supply issues are

of those live current supply issues are certainly going to um be addressed as we

certainly going to um be addressed as we have already been doing over over

have already been doing over over previous um months and years. We work um

previous um months and years. We work um as a regulator to try and enable um

as a regulator to try and enable um access as far as we can. Um so we

access as far as we can. Um so we ourselves are starting to to do some

ourselves are starting to to do some work already at the moment. We are

work already at the moment. We are trying to fill some of those knowledge

trying to fill some of those knowledge gaps that we've outlined and that K's

gaps that we've outlined and that K's again highlighted in the presentation.

again highlighted in the presentation. Looking at mapping out the landscape of

Looking at mapping out the landscape of um current research in this field,

um current research in this field, looking at what the funders are doing,

looking at what the funders are doing, trying to get a good landscape of what's

trying to get a good landscape of what's already out there, and then also

already out there, and then also starting to do things like flesh out um

starting to do things like flesh out um the type of data that we want marketing

the type of data that we want marketing authorization holders to supply to us

authorization holders to supply to us under those new kind of mandatory

under those new kind of mandatory reporting requirements that have come

reporting requirements that have come out in the latest revision of our

out in the latest revision of our legislation. So those are some things

legislation. So those are some things that we're doing and we're really hoping

that we're doing and we're really hoping that others in industry like rumor and

that others in industry like rumor and others and and certainly you've got this

others and and certainly you've got this webinar for example and you recently

webinar for example and you recently have run a a survey which has been

have run a a survey which has been really helpful. So that work that others

really helpful. So that work that others are doing we hope will also take place

are doing we hope will also take place in parallel to that action plan

in parallel to that action plan development but the process for I guess

development but the process for I guess the next big kind of um publication will

the next big kind of um publication will be the action plan and that's like I

be the action plan and that's like I said ne next September time.

said ne next September time. >> You've set me up perfectly for my next

>> You've set me up perfectly for my next two questions Suzanne. Thank you. You

two questions Suzanne. Thank you. You you've made it clear that this is not

you've made it clear that this is not all entirely in the gift of government

all entirely in the gift of government or indeed the VMD and and I think

or indeed the VMD and and I think because of the complexity we understand

because of the complexity we understand that and that you you you absolutely see

that and that you you you absolutely see other elements of the industry

other elements of the industry contributing to it and and as as I said

contributing to it and and as as I said initially rumor here willing to help and

initially rumor here willing to help and contribute in any way we can and right

contribute in any way we can and right across the alliance you'll you'll have

across the alliance you'll you'll have our support. How do you see other

our support. How do you see other elements of the industry um contributing

elements of the industry um contributing to this?

to this? >> Yeah, I'll I'll take that one. So, as I

>> Yeah, I'll I'll take that one. So, as I outlined in the statement of event and

outlined in the statement of event and in the presentation, we all know this is

in the presentation, we all know this is a a complicated problem and it's a

a a complicated problem and it's a long-standing problem and that it's

long-standing problem and that it's going to require all different parts of

going to require all different parts of the industry to contribute in order for

the industry to contribute in order for us to make progress. And that, you know,

us to make progress. And that, you know, if you think about the supply chain,

if you think about the supply chain, that's a massive industry. So we looking

that's a massive industry. So we looking from initial research um the

from initial research um the pharmaceutical companies, manufacturers,

pharmaceutical companies, manufacturers, distributors, prescribers um and farmers

distributors, prescribers um and farmers and end users and we need all of those

and end users and we need all of those um uh participants and stakeholders and

um uh participants and stakeholders and their respective member organizations to

their respective member organizations to be represented. Um I think a lot of the

be represented. Um I think a lot of the required activities that we'll start to

required activities that we'll start to map out are going to be around improving

map out are going to be around improving our communications and sharing

our communications and sharing intelligence so that we have more

intelligence so that we have more transparency regarding um potential

transparency regarding um potential shortages. we have better utilization of

shortages. we have better utilization of available stock. We know that some

available stock. We know that some shortages aren't down to a national

shortages aren't down to a national shortage of product. It's ju just due to

shortage of product. It's ju just due to that product not necessarily getting to

that product not necessarily getting to the places where it needs to get to. Um

the places where it needs to get to. Um I definitely see that there's um

I definitely see that there's um potential for improved forecasting of

potential for improved forecasting of need um to have uh positive impacts both

need um to have uh positive impacts both what we see as our need for vaccines now

what we see as our need for vaccines now but our anticipated need in future as we

but our anticipated need in future as we start to see new disease incursions um

start to see new disease incursions um and thinking about you know commitments

and thinking about you know commitments to purchase. How can we make that um

to purchase. How can we make that um market pull or certainty for what's a

market pull or certainty for what's a commercial industry um more solid? Um

commercial industry um more solid? Um alongside this, you know, we're

alongside this, you know, we're developing a national action plan, but

developing a national action plan, but we need to recognize this is a really

we need to recognize this is a really complex global issue. So supply chains

complex global issue. So supply chains are global. Very little manufacture

are global. Very little manufacture happens here within the UK. Most

happens here within the UK. Most vaccines that we use in the UK are also

vaccines that we use in the UK are also being distributed to other markets. And

being distributed to other markets. And we know from speaking to our regulatory

we know from speaking to our regulatory counterparts in other jurisdictions that

counterparts in other jurisdictions that um other countries are seeing the same

um other countries are seeing the same issues as ours. Some of those same

issues as ours. Some of those same issues will share the same um causality

issues will share the same um causality and therefore the same I guess um

and therefore the same I guess um potential responses and and solutions

potential responses and and solutions and some will be different. But part of

and some will be different. But part of this um collaborative approach will be

this um collaborative approach will be everybody reaching out to their

everybody reaching out to their respective international partners to

respective international partners to understand what the situations are um

understand what the situations are um abroad, whether there are any um

abroad, whether there are any um barriers and challenges that we share in

barriers and challenges that we share in common, what are the opportunities for

common, what are the opportunities for collaboration. Um and I think the other

collaboration. Um and I think the other thing in terms of this whole sort of

thing in terms of this whole sort of multistakeholder collaborative approach

multistakeholder collaborative approach is it's important we don't look at

is it's important we don't look at vaccine availability issues um um

vaccine availability issues um um independently or in isolation. You know

independently or in isolation. You know vaccines are part of a much greater

vaccines are part of a much greater holistic picture with regards to animal

holistic picture with regards to animal health and welfare. Um we need to where

health and welfare. Um we need to where we can reduce our reliance on vaccines

we can reduce our reliance on vaccines where that's appropriate through

where that's appropriate through improved biocurity animal welfare etc.

improved biocurity animal welfare etc. So there's lots of other conversations

So there's lots of other conversations that need to be happening across the

that need to be happening across the industry around this vaccine

industry around this vaccine availability initiative.

availability initiative. >> Yeah, I I think that's really important

>> Yeah, I I think that's really important that we do look internationally because

that we do look internationally because there might well be some lessons we can

there might well be some lessons we can learn there. As you say, Claire, it's

learn there. As you say, Claire, it's it's a global issue. We're not on our

it's a global issue. We're not on our own in terms of facing some of these

own in terms of facing some of these problems. Um

problems. Um >> actually, sorry Chris, I just want to

>> actually, sorry Chris, I just want to some other angles to this as well. um

some other angles to this as well. um you know the UN for example because we

you know the UN for example because we know there's a lot going on across the

know there's a lot going on across the international community more widely than

international community more widely than just regulators already um because it's

just regulators already um because it's such a impactful issue not least in

such a impactful issue not least in relation to um addressing really big

relation to um addressing really big public health and animal health issues

public health and animal health issues like AMR the antimicrobial resistance um

like AMR the antimicrobial resistance um you know and that's been a really good

you know and that's been a really good driver um for the wider kind of

driver um for the wider kind of community to understand why it's such a

community to understand why it's such a big issue that we have availability of

big issue that we have availability of vaccines at the right time at the right

vaccines at the right time at the right place um so we have a a member of staff

place um so we have a a member of staff succumbed to the world organization for

succumbed to the world organization for animal health and she's supporting work

animal health and she's supporting work at that global level and I absolutely we

at that global level and I absolutely we watch this space because there'll be

watch this space because there'll be more coming out from the UN agencies

more coming out from the UN agencies around like that kind of international

around like that kind of international um drawing together of of of um uh

um drawing together of of of um uh different sectors and stakeholders at

different sectors and stakeholders at that kind of international level um

that kind of international level um which will complement and will work with

which will complement and will work with and align with that at the national

and align with that at the national level as well.

level as well. >> Yeah. And and coming back a little bit

>> Yeah. And and coming back a little bit Claire, I I take your point. Um this is

Claire, I I take your point. Um this is a this is a complex issue. This is a we

a this is a complex issue. This is a we have to see vaccine availability in the

have to see vaccine availability in the round of good nutrition, good biocurity,

round of good nutrition, good biocurity, um ensuring hygiene, good management

um ensuring hygiene, good management practices generally. I absolutely get

practices generally. I absolutely get that. But just coming back to your point

that. But just coming back to your point Suzanne I think we are almost a victim

Suzanne I think we are almost a victim of our success in agriculture in that we

of our success in agriculture in that we have absolutely bought into the value

have absolutely bought into the value that vaccines can bring to that mix of

that vaccines can bring to that mix of animal health welfare management

animal health welfare management medicine veterary medicine use um when

medicine veterary medicine use um when you look at other elements of society

you look at other elements of society where you know we're not going to go

where you know we're not going to go there and talk about COVID today but

there and talk about COVID today but there has been suspicion there has been

there has been suspicion there has been resistance there hasn't been the same uh

resistance there hasn't been the same uh acknowledgement and I I um think back to

acknowledgement and I I um think back to the Noah guidelines that sort of

the Noah guidelines that sort of categorize vaccines as category ones and

categorize vaccines as category ones and category twos.

category twos. The category ones are kind of like the

The category ones are kind of like the no-brainers. If you're in that industry,

no-brainers. If you're in that industry, why aren't you using them? And the

why aren't you using them? And the category 2s are more complicated in

category 2s are more complicated in terms of the individual farm story. But

terms of the individual farm story. But generally, I think agriculture's

generally, I think agriculture's embraced them. Kind of takes me on to my

embraced them. Kind of takes me on to my next question. in in the vaccine survey

next question. in in the vaccine survey um the responses we got the survey was

um the responses we got the survey was carried out earlier in the summer and

carried out earlier in the summer and we've we've just seen the presentation

we've we've just seen the presentation from that earlier in the this webinar

from that earlier in the this webinar but that showed that the disparity is

but that showed that the disparity is not equal across the entire industry I

not equal across the entire industry I think there is there are elements of

think there is there are elements of problems in all of the sectors certainly

problems in all of the sectors certainly when you had one of your earlier vaccine

when you had one of your earlier vaccine workshops people from every sector were

workshops people from every sector were saying yes we've seen a bit of an issue

saying yes we've seen a bit of an issue we've seen a bit of an issue but the

we've seen a bit of an issue but the noise is louder in certain elements of

noise is louder in certain elements of the industry.

the industry. So is I suppose that kind of leads us to

So is I suppose that kind of leads us to are there any are there going to be any

are there any are there going to be any priority areas? Will we be seeing uh

priority areas? Will we be seeing uh will we have to do more work in certain

will we have to do more work in certain areas than other areas?

areas than other areas? Well, when I say areas perhaps species

Well, when I say areas perhaps species even

even >> I think that's a really good question.

>> I think that's a really good question. Um I mean I think you were really kind

Um I mean I think you were really kind enough to share some of the outcomes

enough to share some of the outcomes from your survey with us Chris um which

from your survey with us Chris um which is looking at kind of um you know

is looking at kind of um you know seasonality flagging up as potentially a

seasonality flagging up as potentially a big issue here. But I think one of the

big issue here. But I think one of the things that we found, Clar and I, in in

things that we found, Clar and I, in in terms of working through the the the

terms of working through the the the feedback from stakeholders and um whilst

feedback from stakeholders and um whilst we've been writing this um uh statement

we've been writing this um uh statement of intent has been that there's quite a

of intent has been that there's quite a lot of um knowledge about the

lot of um knowledge about the generalized issues that affect vaccines,

generalized issues that affect vaccines, but when we drill down into the

but when we drill down into the specifics per vaccine, per species,

specifics per vaccine, per species, there's a lot of nuance within that. And

there's a lot of nuance within that. And I think what we really see the need for

I think what we really see the need for is is a bit more detailed information at

is is a bit more detailed information at that nuanced level. Um you know

that nuanced level. Um you know seasonality of vaccines may well be an

seasonality of vaccines may well be an influential factor but you know there

influential factor but you know there may be other things that come into play

may be other things that come into play like for example different vaccines.

like for example different vaccines. Some some are harder to make than

Some some are harder to make than others. You know some have processes

others. You know some have processes when you produce them are more likely to

when you produce them are more likely to go wrong. And so I think there's there's

go wrong. And so I think there's there's a lot of nuance within there that we

a lot of nuance within there that we need to understand better. Um and that's

need to understand better. Um and that's definitely some of the work that will be

definitely some of the work that will be um up front, you know, kind of in in as

um up front, you know, kind of in in as we go forward over the coming year. Um

we go forward over the coming year. Um but I think what it also points to um is

but I think what it also points to um is that

that what people need to be proactive and to

what people need to be proactive and to mitigate upcoming issues is the right

mitigate upcoming issues is the right information at the right time. So

information at the right time. So there's a whole piece here about the

there's a whole piece here about the communication. And I think you've

communication. And I think you've already alluded to this about people

already alluded to this about people being having a better forward look but

being having a better forward look but not just having it themselves sharing

not just having it themselves sharing that information with the other people

that information with the other people that can help do something about that

that can help do something about that and mitigate that problem and look for

and mitigate that problem and look for solutions in a sufficiently timely

solutions in a sufficiently timely manner that they are in place before the

manner that they are in place before the problem occurs and and that's you know

problem occurs and and that's you know it's it's a tough nut to crack but

it's it's a tough nut to crack but that's definitely what we're aiming for

that's definitely what we're aiming for and I think you know what Claire's

and I think you know what Claire's outlined um in her presentation around

outlined um in her presentation around having this stakeholder dialogue

having this stakeholder dialogue platform um would would a way that we're

platform um would would a way that we're looking to try and bring together the

looking to try and bring together the right information for the right people

right information for the right people at the right time to help address that.

at the right time to help address that. I don't know if you wanted to add

I don't know if you wanted to add anything to that.

anything to that. >> Yeah, I think just on your question,

>> Yeah, I think just on your question, Chris, about prioritization. I mean,

Chris, about prioritization. I mean, certainly we have hundreds of vaccines

certainly we have hundreds of vaccines authorized and we're going to have to um

authorized and we're going to have to um if we're thinking about trying to um

if we're thinking about trying to um safeguard the supply of those, we're

safeguard the supply of those, we're going to have to drill down into a

going to have to drill down into a smaller subset. And you know, we've

smaller subset. And you know, we've we've explored in the statement of

we've explored in the statement of intent and the the potential um

intent and the the potential um activities as we move forward these

activities as we move forward these prioritization exercises. So considering

prioritization exercises. So considering prioritization of what we might um

prioritization of what we might um consider um critical vaccines or

consider um critical vaccines or critical products and and where we um

critical products and and where we um might consider um priority diseases for

might consider um priority diseases for which there are no current authorized

which there are no current authorized vaccines and and that you know we need

vaccines and and that you know we need to narrow down our list to then take

to narrow down our list to then take activities forward. Um I don't think we

activities forward. Um I don't think we yet have in mind the exact criteria upon

yet have in mind the exact criteria upon which we would determine um those

which we would determine um those prioritization exercises and that's

prioritization exercises and that's something that we'd be looking to do you

something that we'd be looking to do you know with wider stakeholders. I think

know with wider stakeholders. I think the rumor um survey results are really

the rumor um survey results are really interesting because certainly it does

interesting because certainly it does look like the sheep sector in particular

look like the sheep sector in particular is badly impacted at the minute and um

is badly impacted at the minute and um the vaccines that they can't get hold of

the vaccines that they can't get hold of are the in the most part the category

are the in the most part the category one vaccines that you reference Chris

one vaccines that you reference Chris where you know we absolutely see the

where you know we absolutely see the need for those. So there is going to

need for those. So there is going to need to be that piece looking across um

need to be that piece looking across um to see you know where do we concentrate

to see you know where do we concentrate our efforts first and then as Suzanne

our efforts first and then as Suzanne spoken to better understanding the

spoken to better understanding the individual nuance of um the supply

individual nuance of um the supply issues associated with those vaccines in

issues associated with those vaccines in particular.

particular. I'm sitting here no longer farming I

I'm sitting here no longer farming I declare um at the moment but when I was

declare um at the moment but when I was a sheep farmer I suppose I was part of

a sheep farmer I suppose I was part of the problem and not the solution good

the problem and not the solution good because I was guilty of turning up at my

because I was guilty of turning up at my local um country store

local um country store two weeks before I wanted my clustial

two weeks before I wanted my clustial vaccines and expect I took availability

vaccines and expect I took availability for granted and I suppose that's the

for granted and I suppose that's the thing that's come out of the

thing that's come out of the conversations I've listened to over the

conversations I've listened to over the last couple of years for whatever

last couple of years for whatever reasons we can't take that availability

reasons we can't take that availability for granted Ed and if I was still uh

for granted Ed and if I was still uh farming, I think I would be thinking

farming, I think I would be thinking about how do I h how do I give my

about how do I h how do I give my supplier that information earlier in the

supplier that information earlier in the process. I don't know what that would

process. I don't know what that would be. Maybe that's something

be. Maybe that's something you were talking earlier on about what

you were talking earlier on about what other elements of the industry can give

other elements of the industry can give to this. That's something that certainly

to this. That's something that certainly rumor could could take on board with its

rumor could could take on board with its alliance of members.

alliance of members. >> My last question Oh, sorry.

>> My last question Oh, sorry. >> No, sorry. Thanks, Chris. I was just

>> No, sorry. Thanks, Chris. I was just going to echo that because we know that

going to echo that because we know that you know vaccine production and

you know vaccine production and manufacturer is a commercial um

manufacturer is a commercial um situation. Um companies need to know

situation. Um companies need to know that there's a market for their product

that there's a market for their product and we also know it takes time to make

and we also know it takes time to make you know uh batches of vaccine a very

you know uh batches of vaccine a very complicated biological um uh product. So

complicated biological um uh product. So um exactly that you know knowing that

um exactly that you know knowing that there is a market and knowing

there is a market and knowing sufficiently far in advance the size of

sufficiently far in advance the size of that market to then um influence um

that market to then um influence um production chains and um and scheduling.

production chains and um and scheduling. absolutely you know we see as being

absolutely you know we see as being beneficial and I think that's certainly

beneficial and I think that's certainly something that we would want to

something that we would want to understand better from manufacturers the

understand better from manufacturers the type of information that they want um

type of information that they want um and the type of lead in time that they

and the type of lead in time that they need and then yeah certainly look to um

need and then yeah certainly look to um rumor and other organizations to help um

rumor and other organizations to help um you know collect in that information

you know collect in that information >> yeah

>> yeah sorry just to add to that as well we we

sorry just to add to that as well we we get carried away Chris I'm so sorry

get carried away Chris I'm so sorry because I feel quite passionately about

because I feel quite passionately about the subject um we've talked a lot here

the subject um we've talked a lot here talking about kind of end users um and

talking about kind of end users um and manufacturers. actually like let's not

manufacturers. actually like let's not forget about the research community and

forget about the research community and not not forget about kind of the wider

not not forget about kind of the wider kind of spectrum of players that come

kind of spectrum of players that come into the field of funding research um

into the field of funding research um and of amplifying research because you

and of amplifying research because you know what we also hear is when we go and

know what we also hear is when we go and talk to different individual groups and

talk to different individual groups and stakeholders is they're not talking to

stakeholders is they're not talking to each other you know um or they're

each other you know um or they're talking to a very limited section um uh

talking to a very limited section um uh so when we have conversations with the

so when we have conversations with the research community I mean there's

research community I mean there's prioritized exercises that have gone on

prioritized exercises that have gone on have been published um but they have

have been published um but they have mainly focused on the wider research

mainly focused on the wider research community.

community. There's there's a real opportunity here

There's there's a real opportunity here to bring some of those players together

to bring some of those players together um and not just to address immediate

um and not just to address immediate supply issues but also to address that

supply issues but also to address that other second pillar of the statement of

other second pillar of the statement of intent which is around how do we you

intent which is around how do we you know future proof those therapeutic gaps

know future proof those therapeutic gaps that you know some which we already have

that you know some which we already have and some which we might be facing in the

and some which we might be facing in the future. So I think that's you know the

future. So I think that's you know the comms really runs as such a strong

comms really runs as such a strong thread through all of this work.

thread through all of this work. >> Yeah. And and and sorry also just to

>> Yeah. And and and sorry also just to jump in on that. Exactly. And that

jump in on that. Exactly. And that speaks to this

speaks to this >> I will have to stop you in a minute.

>> I will have to stop you in a minute. >> Prioritization of products but

>> Prioritization of products but prioritization of diseases for which we

prioritization of diseases for which we want to see products developed and you

want to see products developed and you know communicating that to researchers.

know communicating that to researchers. And the other thing that we've not

And the other thing that we've not talked much about but is is um uptake of

talked much about but is is um uptake of vaccines and better understanding you

vaccines and better understanding you know the barriers and um drivers for

know the barriers and um drivers for uptake or use of vaccine when it's

uptake or use of vaccine when it's available because um you know that's a

available because um you know that's a whole other segment that drives

whole other segment that drives availability. You know the the greater

availability. You know the the greater the uptake the um you know that then

the uptake the um you know that then becomes a a stimulus for availability.

becomes a a stimulus for availability. But obviously it's a reciprocal um

But obviously it's a reciprocal um arrangement that works both ways. And

arrangement that works both ways. And without giving too much away that that

without giving too much away that that usage thing CLA is something we will be

usage thing CLA is something we will be looking at as rumor we we we do a focus

looking at as rumor we we we do a focus on certain subjects and we intending to

on certain subjects and we intending to work with Noah to do a focus on good

work with Noah to do a focus on good vaccine um utilization so good storage

vaccine um utilization so good storage um the right product at the right time

um the right product at the right time right way of application etc etc so I

right way of application etc etc so I think there's a lot we can do to make

think there's a lot we can do to make sure that where we have vaccines we make

sure that where we have vaccines we make the best use of them Suzanne you you set

the best use of them Suzanne you you set me up nicely just now talking about

me up nicely just now talking about communications really for my last

communications really for my last question. So, um you I think you've done

question. So, um you I think you've done a pretty good job of reaching out to the

a pretty good job of reaching out to the key st core stakeholders in the

key st core stakeholders in the industry, but if there's someone out

industry, but if there's someone out there listening to the webinar today who

there listening to the webinar today who feels they have something to contribute

feels they have something to contribute and perhaps haven't been involved in the

and perhaps haven't been involved in the process so far, how can they get in

process so far, how can they get in touch?

touch? >> Okay, so I mean we've said repeatedly we

>> Okay, so I mean we've said repeatedly we want this to be a really collaborative

want this to be a really collaborative process and and clearly we do. um we've

process and and clearly we do. um we've got to be a little bit careful because

got to be a little bit careful because of the reality factor as to how many

of the reality factor as to how many contact points we can leaz with in in

contact points we can leaz with in in one time. Um so I would say I would

one time. Um so I would say I would encourage anyone who feels like they're

encourage anyone who feels like they're not involved to maybe look and see

not involved to maybe look and see whether any of the stakeholder groups

whether any of the stakeholder groups that they're part of so for example if

that they're part of so for example if they're a member of if they're a member

they're a member of if they're a member of of some other um organization that is

of of some other um organization that is already contributing um to reach out to

already contributing um to reach out to their kind of contact point in the

their kind of contact point in the organization and make sure their ideas

organization and make sure their ideas are fed in um through that contact

are fed in um through that contact point. But obviously if you've got

point. But obviously if you've got stakeholders who are listening to this

stakeholders who are listening to this who um are not part of one of those

who um are not part of one of those organizations or are not aware as to

organizations or are not aware as to whether or not their organization has

whether or not their organization has been involved um then they can either

been involved um then they can either reach out um to us uh directly or I'm

reach out um to us uh directly or I'm potentially I guess Chris maybe Rumor

potentially I guess Chris maybe Rumor could um field some questions if it's if

could um field some questions if it's if it's your core stakeholder group um and

it's your core stakeholder group um and we'll certainly take that on board and

we'll certainly take that on board and we're keen to make sure that there are

we're keen to make sure that there are no stakeholder groups that are not being

no stakeholder groups that are not being represented there um or when I say

represented there um or when I say groups I mean also organizations um So

groups I mean also organizations um So that's absolutely welcomed. Um and then

that's absolutely welcomed. Um and then we'll include those uh additional

we'll include those uh additional contact points as we move forward with

contact points as we move forward with some of those processes that Clara set

some of those processes that Clara set out around the planning workshops um and

out around the planning workshops um and the other structures that we'll um

the other structures that we'll um operate this initiative through. Um we

operate this initiative through. Um we are also going to operate a wider comms

are also going to operate a wider comms program because we talk about comms so

program because we talk about comms so much through this process because

much through this process because there's the kind of comms about this

there's the kind of comms about this initiative um which is important and

initiative um which is important and we're going to be looking at having

we're going to be looking at having things like um some type of external web

things like um some type of external web page or landing page um or shareepoint

page or landing page um or shareepoint site through which people access kind of

site through which people access kind of information about what's going on

information about what's going on specifically um and we will be hosting

specifically um and we will be hosting you know stakeholder workshops as the um

you know stakeholder workshops as the um uh action plan um is being delivered so

uh action plan um is being delivered so that people can stay aware of what's

that people can stay aware of what's happening under it. But in terms of the

happening under it. But in terms of the wider comms piece, there's a lot more to

wider comms piece, there's a lot more to do. Um, you know, there's a whole comm's

do. Um, you know, there's a whole comm's piece about just raising awareness about

piece about just raising awareness about how important vaccines are. I know we've

how important vaccines are. I know we've talked about the fact that lots of

talked about the fact that lots of people are aware of it, but I think

people are aware of it, but I think there's always wider reach and it's

there's always wider reach and it's really important that we get that kind

really important that we get that kind of recognition about the um about the

of recognition about the um about the issues that are occurring and how

issues that are occurring and how important is to resolve them um in those

important is to resolve them um in those other wider forums, the public health

other wider forums, the public health forum for example, you know, those wider

forum for example, you know, those wider kind of forums which can really lend

kind of forums which can really lend kind of um you know power to what we're

kind of um you know power to what we're doing and can really make sure that it's

doing and can really make sure that it's woven into other strands of activities

woven into other strands of activities which will give it more um weight and

which will give it more um weight and more kind of um I mean funding for

more kind of um I mean funding for example getting involved in some of

example getting involved in some of those wider funding initiatives would be

those wider funding initiatives would be really important. So we need to raise

really important. So we need to raise the profile of it and that's something

the profile of it and that's something for everyone to do um uh throughout the

for everyone to do um uh throughout the kind of uh groups that are that are

kind of uh groups that are that are supporting this work. So I hope that

supporting this work. So I hope that covers some of those angles off. I mean

covers some of those angles off. I mean we definitely need comm strategy and

we definitely need comm strategy and that's going to be developed alongside

that's going to be developed alongside the action plan as one of those strands

the action plan as one of those strands of that. Um but there will be kind of

of that. Um but there will be kind of you know work underway over the next

you know work underway over the next year as well to to make sure we're

year as well to to make sure we're getting messaging out there.

getting messaging out there. >> Well just to re reassure you rumor will

>> Well just to re reassure you rumor will be very happy to share in any of those

be very happy to share in any of those communications and we we've um I think

communications and we we've um I think we've made the point there that the

we've made the point there that the stakeholders all of all of the

stakeholders all of all of the stakeholders you you've contacted will

stakeholders you you've contacted will be keen to follow the progress I think

be keen to follow the progress I think of this. So, I know you don't have all

of this. So, I know you don't have all of the answers today, but as you as you

of the answers today, but as you as you develop those communications, as you

develop those communications, as you say, SA as you say, Suzanne, we'll be

say, SA as you say, Suzanne, we'll be keen to help. And um for the 35,000

keen to help. And um for the 35,000 sheet producers out there, please

sheet producers out there, please contact NSA or NFU to input your um your

contact NSA or NFU to input your um your your concerns or your interest because

your concerns or your interest because I'm sure you don't want 35,000 emails

I'm sure you don't want 35,000 emails ending up in your inbox when you get

ending up in your inbox when you get back from from uh your travels. Uh

back from from uh your travels. Uh ladies, thanks very much. I think I'll

ladies, thanks very much. I think I'll draw our Q&A to a close today. That's

draw our Q&A to a close today. That's been a really useful bit of additional

been a really useful bit of additional insight into um what we hope is a really

insight into um what we hope is a really what we think is a really important

what we think is a really important initiative for the industry. What we

initiative for the industry. What we hope will be a very successful

hope will be a very successful initiative uh in terms of um improving

initiative uh in terms of um improving the situation for vaccine availability

the situation for vaccine availability in the future. But we don't

in the future. But we don't underestimate the challenge and we

underestimate the challenge and we completely understand that it's not all

completely understand that it's not all in your gift and we're all here to

in your gift and we're all here to contribute and do what we can. So, uh

contribute and do what we can. So, uh thank you for your time today. Thanks

thank you for your time today. Thanks for the presentation and uh we look

for the presentation and uh we look forward to what comes next. Thank you.

forward to what comes next. Thank you. >> Thanks Chris.

>> So that Q&A um brings us to the end of our webinar. Uh I think what we've

our webinar. Uh I think what we've established over the course of this is

established over the course of this is that vaccines play a vital part in our

that vaccines play a vital part in our efforts to prevent and manage disease.

efforts to prevent and manage disease. And clearly the development,

And clearly the development, manufacturer and regulation of these

manufacturer and regulation of these medicines is not like making nuts and

medicines is not like making nuts and bolts as I referred to earlier on. But

bolts as I referred to earlier on. But re we rely on the efforts of pharma

re we rely on the efforts of pharma companies and the regulator to ensure

companies and the regulator to ensure that they remain available to us uh and

that they remain available to us uh and indeed potentially new vaccines can come

indeed potentially new vaccines can come online to tackle new and emerging

online to tackle new and emerging diseases. There's a lot of work ahead to

diseases. There's a lot of work ahead to ensure that we can continue to have

ensure that we can continue to have those vaccines and as end users we need

those vaccines and as end users we need to do all that we can to aid that

to do all that we can to aid that process. just like to say thank you to

process. just like to say thank you to all of those who stayed online. I'm sure

all of those who stayed online. I'm sure some people will watch uh elements of

some people will watch uh elements of this um online afterwards. Um Mary's

this um online afterwards. Um Mary's going to drop uh a link to the page on

going to drop uh a link to the page on our website where the the full recording

our website where the the full recording will be uh can be found and if you're

will be uh can be found and if you're able to watch our future webinars um we

able to watch our future webinars um we look forward to you joining us in

look forward to you joining us in future. So thank you very much for your

future. So thank you very much for your attention today. I hope you found it

attention today. I hope you found it interesting and useful and we look

interesting and useful and we look forward to seeing you in the future.

forward to seeing you in the future. Thank you.

Thank you. Goodbye.

Click on any text or timestamp to jump to that moment in the video

Most transcripts ready in under 5 seconds

One-Click Copy125+ LanguagesSearch ContentJump to Timestamps

Paste YouTube URL

Enter any YouTube video link to get the full transcript

Most transcripts ready in under 5 seconds

Get Our Chrome Extension

Get transcripts instantly without leaving YouTube. Install our Chrome extension for one-click access to any video's transcript directly on the watch page.

Add to Chrome — Free

Works with YouTube, Coursera, Udemy and more educational platforms

Get Instant Transcripts: Just Edit the Domain in Your Address Bar!

YouTube

←

→

↻

https://www.youtube.com/watch?v=UF8uR6Z6KLc

YoutubeToText

←

→

↻

https://youtubetotext.net/watch?v=UF8uR6Z6KLc

YouTube TranscriptPreparing your results…

YouTube Transcript:RUMA Agriculture Webinar - The future for vaccine Availability for the UK animal health market